Security
Quince Therapeutics, Inc. Common Stock · QNCX
QNCXNASDAQCommon stockHistorical · closed Oct 9, 2026CIK 1662774Updated Oct 27, 2026
Name history
Quince Therapeutics, Inc. · through Oct 9, 2026Cortexyme, Inc. · through Aug 1, 2022
Current security for this SEC filerIRLA · NASDAQ
QNCX price & chart
Historical security
This listing closed Oct 9, 2026. Live provider charts are shown only for current listings.
Current security: IRLA
About the company
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
In the news
Quince Therapeutics to Participate in September 2026 Investor Conferences ↗
Seeking Alpha
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript ↗
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript ↗
Quince Therapeutics GAAP EPS of -$12.31 misses by $0.02 ↗
SEC disclosures
Quince Therapeutics, Inc. files definitive proxy statement ↗
Recent filings
144 filing
3 filing
3 filing
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G - filed by PERCEPTIVE ADVISORS LLC regarding IRulya Therapeutics Inc.
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 5.02, 5.03, 7.01, 8.01, 9.01
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
DEFA14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 109,899,000Source | 126,519,000Source | 123,995,000Source | 117,210,000Source | 134,829,000Source | 26,623,000Source | 107,089,000Source | 159,292,000Source | 93,523,000Source | 114,478,000Source | 167,900,000Source | 103,910,000Source |
| Property, Plant and Equipment, NetUSD | 616,000Source | 208,000Source | 506,000Source | 573,000Source | 246,000Source | 550,000Source | 448,000Source | 234,000Source | 595,000Source | 315,000Source | 234,000Source | 393,000Source |
| GoodwillUSD | 0Source | 0Source | — | — | 0Source | — | — | 17,245,000Source | — | 0Source | 17,625,000Source | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 67,726,000Source | 64,528,000Source | 0Source | 67,566,000Source | 61,793,000Source | 0Source | 62,365,000Source | 62,253,000Source | 67,819,000Source | 60,045,000Source | 63,672,000Source | 5,900,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,452,000Source | — | 115,981,000Source | 16,826,000Source | — | 18,163,000Source | 7,771,000Source | — | 5,809,000Source | — | — | — |
| Assets, CurrentUSD | 29,202,000Source | 51,718,000Source | 123,411,000Source | 37,345,000Source | 63,438,000Source | 25,580,000Source | 33,829,000Source | 70,439,000Source | 22,896,000Source | 44,036,000Source | 77,440,000Source | 93,748,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,914,000Source | 3,871,000Source | 7,430,000Source | 2,637,000Source | 3,993,000Source | 7,417,000Source | 2,230,000Source | 2,616,000Source | 5,144,000Source | 3,252,000Source | 2,381,000Source | 3,567,000Source |
| Operating Lease, Right-of-Use AssetUSD | 481,000Source | 559,000Source | 0Source | 507,000Source | 554,000Source | 415,000Source | 493,000Source | 498,000Source | 453,000Source | 498,000Source | 385,000Source | 291,000Source |
| Other Assets, NoncurrentUSD | 11,874,000Source | 9,506,000Source | 78,000Source | 11,219,000Source | 8,798,000Source | 78,000Source | 9,954,000Source | 8,467,000Source | 1,760,000Source | 9,584,000Source | 8,456,000Source | 0Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 108,840,000Source | 81,587,000Source | 15,508,000Source | 105,474,000Source | 87,861,000Source | 10,951,000Source | 88,508,000Source | 85,115,000Source | 129,237,000Source | 84,332,000Source | 82,816,000Source | 3,317,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 54,000Source | 43,000Source | 1,000Source | 53,000Source | 43,000Source | 14,000Source | 44,000Source | 43,000Source | 55,000Source | 44,000Source | 43,000Source | 36,000Source |
| Additional Paid in CapitalUSD | 415,705,000Source | — | 460,447,000Source | 413,078,000Source | — | 435,587,000Source | 408,082,000Source | — | 418,932,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -420,993,000Source | -364,014,000Source | -500,027,000Source | -407,551,000Source | -358,522,000Source | -424,539,000Source | -391,502,000Source | -330,793,000Source | -460,451,000Source | -376,472,000Source | -319,644,000Source | -288,259,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 6,293,000Source | 3,419,000Source | 4,255,000Source | 6,156,000Source | 1,087,000Source | 4,610,000Source | 1,957,000Source | 1,825,000Source | 5,750,000Source | -35,000Source | 3,047,000Source | -289,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,059,000Source | 44,932,000Source | -35,324,000Source | 11,736,000Source | 46,968,000Source | 15,672,000Source | 18,581,000Source | 74,177,000Source | -35,714,000Source | 30,146,000Source | 85,084,000Source | 100,593,000Source |
| Additional Paid in Capital, Common StockUSD | — | 405,484,000Source | — | — | 404,360,000Source | — | — | 403,102,000Source | — | 406,609,000Source | 401,638,000Source | 389,105,000Source |
| Liabilities and EquityUSD | 109,899,000Source | 126,519,000Source | 123,995,000Source | 117,210,000Source | 134,829,000Source | 26,623,000Source | 107,089,000Source | 159,292,000Source | 93,523,000Source | 114,478,000Source | 167,900,000Source | 103,910,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 26,044,000Source | 5,425,000Source | 8,500,000Source | 7,467,000Source | 10,321,000Source | 8,768,000Source | 8,356,000Source | 9,838,000Source | 43,226,000Source | 7,278,000Source | 9,572,000Source | 3,069,000Source |
| Operating Lease, Liability, CurrentUSD | 114,000Source | 101,000Source | 0Source | 112,000Source | 94,000Source | 113,000Source | 102,000Source | 96,000Source | 115,000Source | 96,000Source | 64,000Source | 377,000Source |
| Accounts Payable, CurrentUSD | 3,403,000Source | 1,622,000Source | 4,636,000Source | 1,759,000Source | 2,405,000Source | 5,392,000Source | 3,008,000Source | 2,070,000Source | 2,223,000Source | 2,903,000Source | 2,033,000Source | 570,000Source |
| Operating Lease, Liability, NoncurrentUSD | 359,000Source | 450,000Source | 0Source | 387,000Source | 453,000Source | 293,000Source | 383,000Source | 394,000Source | 330,000Source | 394,000Source | 321,000Source | 0Source |
| Deferred Income Tax Liabilities, NetUSD | 5,593,000Source | 5,382,000Source | — | 5,595,000Source | 5,173,000Source | — | 5,172,000Source | 5,177,000Source | 0Source | 4,963,000Source | 5,304,000Source | 248,000Source |
| Other Liabilities, NoncurrentUSD | 778,000Source | 643,000Source | 716,000Source | 745,000Source | 609,000Source | 1,196,000Source | 716,000Source | 599,000Source | 1,570,000Source | 685,000Source | 587,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,121,000Source | 3,803,000Source | 3,864,000Source | 5,708,000Source | 2,916,000Source | 3,376,000Source | 5,348,000Source | 3,020,000Source | 10,608,000Source | 4,375,000Source | 3,436,000Source | 2,499,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 26,300,000Source | 47,800,000Source | 116,000,000Source | 34,700,000Source | 59,400,000Source | 18,200,000Source | 31,600,000Source | 67,800,000Source | 17,800,000Source | 40,800,000Source | 75,100,000Source | 90,200,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 4,963,000Source | 5,304,000Source | — |
| Long-term DebtUSD | 0Source | 14,899,000Source | — | 16,989,000Source | 13,834,000Source | — | 15,266,000Source | 13,518,000Source | 0Source | 14,321,000Source | 13,429,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 17,520,000Source | — | 0Source | — | — | 0Source | — | — | 18,026,000Source | — | — | — |
| Short-term Investments | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -56,828,000Source | -31,385,000Source | -51,660,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,286,000Source | 1,386,000Source | 5,105,000Source | 4,746,000Source | 5,220,000Source | 16,618,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 5,911,000Source | 22,000Source | -940,000Source | 927,000Source | -288,000Source | -5,943,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -5,589,000Source | -45,000Source | -258,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,627,000Source | -9,601,000Source | -41,425,000Source | -31,904,000Source | -18,292,000Source | -44,038,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 12,000,000Source | 10,898,000Source | 23,227,000Source | 21,908,000Source | -5,758,000Source | 18,002,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 148,000Source | 352,000Source | 257,000Source | 160,000Source | 133,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 9,443,000Source | 87,000Source | 17,909,000Source | -4,775,000Source | 143,000Source | 707,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 12,354,000Source | 1,559,000Source | -403,000Source | -14,540,000Source | -23,827,000Source | -25,145,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,452,000Source | 2,675,000Source | 115,981,000Source | 16,826,000Source | 18,163,000Source | 7,771,000Source | 5,809,000Source | 6,212,000Source | 20,752,000Source | 44,579,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 29,000Source | 53,000Source | 234,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -1,462,000Source | 175,000Source | -114,000Source | 231,000Source | 80,000Source | 184,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,255,000Source | 1,124,000Source | 12,093,000Source | 1,273,000Source | 1,286,000Source | 1,386,000Source | 5,105,000Source | 4,746,000Source | 5,220,000Source | 16,618,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 26,300,000Source | 47,800,000Source | 116,000,000Source | 34,700,000Source | 18,200,000Source | 31,600,000Source | 17,800,000Source | 40,800,000Source | 75,100,000Source | 90,200,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 100,000Source | 200,000Source | 300,000Source | 204,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 477,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,281,000Source | 3,630,000Source | 16,626,000Source | 3,342,000Source | 4,267,000Source | 4,789,000Source | 15,047,000Source | 17,580,000Source | 17,695,000Source | 26,012,000Source |
| GoodwillUSD | — | — | 0Source | 0Source | — | — | — | — | — | 0Source | 17,625,000Source | 0Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | — | — | — | — | 825,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 17,130,000Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | 0Source | — | — | 67,808,000Source | 0Source | — | 0Source | 5,900,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -46,000Source | 13,000Source | 75,000Source | 67,000Source | -5,339,000Source | 47,000Source | 3,214,000Source | 87,000Source | 197,000Source | -284,000Source |
| Investment Income, InterestUSD | — | — | 300,000Source | 683,000Source | 584,000Source | 311,000Source | 160,000Source | 406,000Source | 1,244,000Source | 2,929,000Source | 3,478,000Source | 1,068,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -13,442,000Source | -5,492,000Source | -75,488,000Source | -16,049,000Source | 35,912,000Source | -15,030,000Source | -83,979,000Source | -56,828,000Source | -31,385,000Source | -51,660,000Source |
| Operating ExpensesUSD | — | — | 13,430,000Source | 5,863,000Source | 79,782,000Source | 10,427,000Source | 14,590,000Source | 14,858,000Source | 58,068,000Source | 57,285,000Source | 34,620,000Source | 52,015,000Source |
| Operating Lease, ExpenseUSD | — | — | 38,000Source | 35,000Source | 43,000Source | 38,000Source | 37,000Source | 35,000Source | 200,000Source | 100,000Source | — | — |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 0Source | 66,000Source | 136,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -58,000Source | 150,000Source | 152,000Source | -29,000Source | 1,719,000Source | -87,000Source | 486,000Source | -676,000Source | -102,000Source | -997,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 113,781,000Source | 75,021,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 608,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 87,000Source | 220,000Source | 225,000Source | 149,000Source | 148,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Gain (Loss) on Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -13,430,000Source | -5,863,000Source | -79,782,000Source | -10,427,000Source | -14,590,000Source | -14,858,000Source | -58,068,000Source | -57,285,000Source | -34,620,000Source | -52,015,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -58,000Source | 150,000Source | 152,000Source | -29,000Source | 1,719,000Source | -87,000Source | 486,000Source | -676,000Source | -102,000Source | -997,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | -14,983,000Source | -80,765,000Source | -56,741,000Source | -31,582,000Source | -51,944,000Source |
| Income Tax Expense (Benefit)USD | — | — | -46,000Source | 13,000Source | 75,000Source | 67,000Source | -5,339,000Source | 47,000Source | 3,214,000Source | 87,000Source | 197,000Source | -284,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -13,442,000Source | -5,492,000Source | -75,488,000Source | -16,049,000Source | 35,912,000Source | -15,030,000Source | -83,979,000Source | -56,828,000Source | -31,385,000Source | -51,660,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.25Source | -0.13Source | -12.31Source | -68.75Source | 3.6Source | -3.42Source | -1.68Source | -1.31Source | -0.84Source | -1.54Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.25Source | -0.13Source | -12.31Source | -68.75Source | 2.88Source | -3.42Source | -1.68Source | -1.31Source | -0.84Source | -1.54Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 53,951,371Source | 43,164,136Source | 6,132,845Source | 233,431Source | 9,120,267Source | 4,394,119Source | 50,096,897Source | 43,262,269Source | 37,237,149Source | 33,496,534Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 53,951,371Source | 43,164,136Source | 6,132,845Source | 233,431Source | 9,190,354Source | 4,394,119Source | 50,096,897Source | 43,262,269Source | 37,237,149Source | 33,496,534Source |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | — | — | — | — | — | — | 2,500,000Source | 2,200,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 8,803,000Source | 132,000Source | 61,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 36,000Source | 32,000Source | 142,000Source | 186,000Source | 322,000Source | 204,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 477,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,281,000Source | 3,630,000Source | 16,626,000Source | 3,342,000Source | 4,267,000Source | 4,789,000Source | 15,047,000Source | 17,580,000Source | 17,695,000Source | 26,012,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 17,130,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -56,470,000Source | -22,397,000Source | -27,375,000Source | -48,191,000Source |
| Investment Income, InterestUSD | — | — | 300,000Source | 683,000Source | 584,000Source | 311,000Source | 160,000Source | 406,000Source | 1,244,000Source | 2,929,000Source | 3,478,000Source | 1,068,000Source |
| Operating ExpensesUSD | — | — | 13,430,000Source | 5,863,000Source | 79,782,000Source | 10,427,000Source | 14,590,000Source | 14,858,000Source | 58,068,000Source | 57,285,000Source | 34,620,000Source | 52,015,000Source |
| Operating Lease, ExpenseUSD | — | — | 38,000Source | 35,000Source | 43,000Source | 38,000Source | 37,000Source | 35,000Source | 200,000Source | 100,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 8,083,000Source | 4,916,000Source | 5,461,000Source | 6,553,000Source | 6,845,000Source | 8,145,000Source | 35,382,000Source | 18,590,000Source | 9,447,000Source | 25,178,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
Offerings
Registration 333-297903
Filing attachments
d123526dex991.htm · 8-K · 2026-10-19
CORPORATE PRESENTATION OCTOBER 2026 Exhibit 99.1 DISCLAIMERS The information in this Presentation has been prepared by IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc., “IRulya”, and the “company”) and contains information pertaining to the business and operations of the company. The information contained in this Presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available data, internally developed data as well as thir…
Read attachment ↗d172110dex991.htm · 8-K · 2026-10-09
Exhibit 99.1 Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph. D. Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., …
Read attachment ↗qncx-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 3 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an asset purchase agreement (the "APA") with Ayma Therapeutics Inc., a Delaware corporation, ("Ayma" or "Buyer") pursuant to which, on September 8, 2026 (the "Closing Date"), …
Read attachment ↗d379347dex991.htm · 8-K · 2026-08-17
EX-99.1 2 d379347dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 QUINCE THERAPEUTICS, INC., AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On May 18, 2026, Quince Therapeutics, Inc., a Delaware corporation (the “Company” or “Quince”), acquired Orphai Therapeutics, LLC (formerly Orphai Therapeutics, Inc., “Orphai”), a Delaware limited liability company and wholly owned subsidiary of Orphai Holdings Therapeutics, Inc., a Delaware corporation (“HoldCo”), in accord…
Read attachment ↗d163839dex991.htm · 8-K · 2026-08-14
EX-99.1 2 d163839dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financ…
Read attachment ↗d135388dex992.htm · 8-K/A · 2026-05-18
EX-99.2 2 d135388dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeks Pha…
Read attachment ↗